Dr. Choueiri on the Research With Immunotherapy in RCC

Toni Choueiri, MD
Published: Friday, Oct 13, 2017



Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses research involving immunotherapy regimens for patients with renal cell carcinoma (RCC).

There is ongoing research investigating patients who progressed on prior immunotherapy regimens and received cabozantinib (Cabometyx). Those patients experienced a beneficial response with cabozantinib compared to everolimus, states Choueiri.



Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses research involving immunotherapy regimens for patients with renal cell carcinoma (RCC).

There is ongoing research investigating patients who progressed on prior immunotherapy regimens and received cabozantinib (Cabometyx). Those patients experienced a beneficial response with cabozantinib compared to everolimus, states Choueiri.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x